Donor T cells may help prevent relapse of acute myeloid leukemia after stem cell transplants
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation
This study is looking at how immune cells from stem cell donors can help fight off leukemia in patients who have received a transplant for acute myeloid leukemia, with the goal of finding better ways to keep the cancer from coming back.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10877187 on NIH RePORTER |
What this research studies
This research investigates how donor immune cells can recognize and eliminate leukemia cells in patients who have undergone allogeneic stem cell transplantation for acute myeloid leukemia (AML). The study focuses on understanding the specific immune responses that can prevent relapse of AML by analyzing T cell responses to minor histocompatibility antigens. By collecting and examining human tissue samples from patients with matched related donors, the researchers aim to identify the key immune factors that contribute to successful treatment outcomes. This approach could lead to improved strategies for enhancing the effectiveness of stem cell transplants in AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-risk acute myeloid leukemia who are undergoing allogeneic stem cell transplantation.
Not a fit: Patients with low-risk AML or those who are not candidates for stem cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prevention of AML relapse after stem cell transplantation, improving survival rates for patients.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses in similar contexts, suggesting potential for success in this approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Vincent, Benjamin G — Univ of North Carolina Chapel Hill
- Study coordinator: Vincent, Benjamin G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.